From METTL3 PROTACs to pyroptosis-coupled design: a medicinal chemistry agenda for next-generation targeted degraders
Medicinal Chemistry Research · 2026-05 · 35 (5) · 867-870
DOI: 10.1007/s00044-026-03535-4 ↗Kurz gefasst
Leserbrief in der Zeitschrift Medicinal Chemistry Research, online erschienen am 06.03.2026. Verfasst von M Vijayasimha. Beteiligte Einrichtung: Department of MLT, University Institute of Allied Health Science, Chandigarh University, Mohali, 140413, Punjab, India. vijaya.e19133@cumail.in. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of MLT, University Institute of Allied Health Science, Chandigarh University, Mohali, 140413, Punjab, India. vijaya.e19133@cumail.in.
Zitieren
APA
Vijayasimha, M. (2026). From METTL3 PROTACs to pyroptosis-coupled design: a medicinal chemistry agenda for next-generation targeted degraders. Medicinal Chemistry Research, 35(5), 867-870. https://doi.org/10.1007/s00044-026-03535-4
Vancouver
Vijayasimha M. From METTL3 PROTACs to pyroptosis-coupled design: a medicinal chemistry agenda for next-generation targeted degraders. Medicinal Chemistry Research. 2026;35(5):867-870. doi:10.1007/s00044-026-03535-4
BibTeX
@article{Vijayasimha2026,
author = {Vijayasimha, M},
title = {From METTL3 PROTACs to pyroptosis-coupled design: a medicinal chemistry agenda for next-generation targeted degraders},
journal = {Medicinal Chemistry Research},
year = {2026},
volume = {35},
number = {5},
pages = {867--870},
doi = {10.1007/s00044-026-03535-4}
}
EUVIMED